Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2003-07

AUTHORS

G. J. Peters, P. Noordhuis, A. B. P. Van Kuilenburg, J. H. Schornagel, H. Gall, S. L. Turner, M. S. Swart, D. Voorn, A. H. Van Gennip, J. Wanders, U. Holwerda, K. Smid, G. Giaccone, P. Fumoleau, C. J. Van Groeningen

ABSTRACT

S-1 is an oral formulation of ftorafur (FT), oxonic acid and 5-chloro-2,4-dihydroxypyridine (CDHP) at a molar ratio of 1:0.4:1. FT is a 5-fluorouracil (5-FU) prodrug, CDHP is a dihydropyrimidine dehydrogenase (DPD) inhibitor and oxonic acid is an inhibitor of 5-FU phosphoribosylation in the gastrointestinal mucosa and was included to prevent gastrointestinal toxicity. We determined the pharmacokinetics of S-1 in 28 patients at doses of 25, 35, 40 and 45 mg/m(2). The plasma C(max) values of FT, 5-FU, oxonic acid and CDHP increased dose-dependently and after 1-2 h were in the ranges 5.8-13 microM, 0.4-2.4 microM, 0.026-1.337 microM, and 1.1-3.6 microM, respectively. Uracil levels, indicative of DPD inhibition, also increased dose-dependently from basal levels of 0.03-0.25 microM to 3.6-9.4 microM after 2-4 h, and 0.09-0.9 microM was still present after 24 h. The pharmacokinetics of CDHP and uracil were linear over the dose range. The areas under the plasma concentration curves (AUC) for CDHP and uracil were in the ranges 418-1735 and 2281-8627 micromol x min/l, respectively. The t(1/2) values were in the ranges 213-692 and 216-354 min, respectively. Cumulative urinary excretion of FT was predominantly as 5-FU and was 2.2-11.9%; the urinary excretion of both fluoro-beta-alanine and uracil was generally maximal between 6 and 18 h. During 28-day courses with twice-daily S-1 administration, 5-FU and uracil generally increased. Before each intake of S-1, 5-FU varied between 0.5 and 1 microM and uracil was in the micromolar range (up to 7 microM), indicating that effective DPD inhibition was maintained during the course. In a biopsy of an esophageal adenocarcinoma metastasis that had regressed, thymidylate synthase, the target of 5-FU, was inhibited 50%, but increased four- to tenfold after relapse in subsequent biopsies. In conclusion, oral S-1 administration resulted in prolonged exposure to micromolar 5-FU concentrations due to DPD inhibition, and the decrease in uracil levels after 6 h followed the pattern of CDHP and indicates reversible DPD inhibition. More... »

PAGES

1-12

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-003-0617-9

DOI

http://dx.doi.org/10.1007/s00280-003-0617-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1036282560

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/12739060


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Area Under Curve", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biological Availability", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Half-Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Metabolic Clearance Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oxonic Acid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tegafur", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tissue Distribution", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Uracil", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "VU University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007\u00a0MB, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Peters", 
        "givenName": "G. J.", 
        "id": "sg:person.01255301342.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255301342.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "VU University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007\u00a0MB, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Noordhuis", 
        "givenName": "P.", 
        "id": "sg:person.01171546142.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171546142.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Academic Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.5650.6", 
          "name": [
            "Laboratory of Genetic Metabolic Diseases, Academic Medical Center, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Van Kuilenburg", 
        "givenName": "A. B. P.", 
        "id": "sg:person.010124200377.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010124200377.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Antoni van Leeuwenhoek Hospital", 
          "id": "https://www.grid.ac/institutes/grid.430814.a", 
          "name": [
            "Department of Internal Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schornagel", 
        "givenName": "J. H.", 
        "id": "sg:person.0600513472.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0600513472.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "VU University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007\u00a0MB, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gall", 
        "givenName": "H.", 
        "id": "sg:person.01023051473.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023051473.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Antoni van Leeuwenhoek Hospital", 
          "id": "https://www.grid.ac/institutes/grid.430814.a", 
          "name": [
            "Department of Internal Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Turner", 
        "givenName": "S. L.", 
        "id": "sg:person.0606744057.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0606744057.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Antoni van Leeuwenhoek Hospital", 
          "id": "https://www.grid.ac/institutes/grid.430814.a", 
          "name": [
            "Department of Internal Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Swart", 
        "givenName": "M. S.", 
        "id": "sg:person.01256606405.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01256606405.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "VU University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007\u00a0MB, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Voorn", 
        "givenName": "D.", 
        "id": "sg:person.01346612643.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346612643.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Academic Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.5650.6", 
          "name": [
            "Laboratory of Genetic Metabolic Diseases, Academic Medical Center, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Van Gennip", 
        "givenName": "A. H.", 
        "id": "sg:person.01220376041.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220376041.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "NDDO Oncology, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wanders", 
        "givenName": "J.", 
        "id": "sg:person.01307713100.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307713100.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "VU University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Holwerda", 
        "givenName": "U.", 
        "id": "sg:person.01347171204.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347171204.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "VU University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007\u00a0MB, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Smid", 
        "givenName": "K.", 
        "id": "sg:person.01232364243.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232364243.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "VU University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007\u00a0MB, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Giaccone", 
        "givenName": "G.", 
        "id": "sg:person.01304747074.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304747074.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "EORTC\u2014New Drug Development Group, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fumoleau", 
        "givenName": "P.", 
        "id": "sg:person.01101667531.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01101667531.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "VU University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007\u00a0MB, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Van Groeningen", 
        "givenName": "C. J.", 
        "id": "sg:person.016122500204.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016122500204.87"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1054/drup.1999.0089", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000143703"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(98)00058-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004034553"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(01)00371-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008444022"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-2952(94)00444-q", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012048074"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0378-4347(01)00203-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016987868"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00685670", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017013439", 
          "https://doi.org/10.1007/bf00685670"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00685670", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017013439", 
          "https://doi.org/10.1007/bf00685670"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1081/cnv-120000360", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018308252"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archneur.1970.00480260061008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024508314"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/13543784.5.6.637", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025883442"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00662639", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026508229", 
          "https://doi.org/10.1007/bf00662639"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00662639", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026508229", 
          "https://doi.org/10.1007/bf00662639"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0925-4439(02)00082-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026544769"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-2952(89)90187-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027438015"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-2952(89)90187-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027438015"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000138581", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027697939"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002800050561", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028328879", 
          "https://doi.org/10.1007/s002800050561"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/00498259609046718", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029977116"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-1-59259-725-3_5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035390634", 
          "https://doi.org/10.1007/978-1-59259-725-3_5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0277-5379(87)90053-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036522081"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(19911101)68:9<1903::aid-cncr2820680910>3.0.co;2-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036845106"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0959-8049(95)00217-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041155362"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.1980.156", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041499966", 
          "https://doi.org/10.1038/clpt.1980.156"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0959-8049(93)90129-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044367856"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0378-4347(96)00429-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046560228"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074255186", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074515759", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.8.2439", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074549863"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074570373", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2000.18.14.2772", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074667570"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074733629", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074797879", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3727/096504001108747729", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074838513"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.22.4267", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074954342"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076942345", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079562315", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079597830", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079977592", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080114929", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081600900", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082466563", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1994.12.10.2035", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082570398"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082895728", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1998.16.1.301", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083201650"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1998.16.4.1450", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083246640"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083251777", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083320099", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083370636", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2003-07", 
    "datePublishedReg": "2003-07-01", 
    "description": "S-1 is an oral formulation of ftorafur (FT), oxonic acid and 5-chloro-2,4-dihydroxypyridine (CDHP) at a molar ratio of 1:0.4:1. FT is a 5-fluorouracil (5-FU) prodrug, CDHP is a dihydropyrimidine dehydrogenase (DPD) inhibitor and oxonic acid is an inhibitor of 5-FU phosphoribosylation in the gastrointestinal mucosa and was included to prevent gastrointestinal toxicity. We determined the pharmacokinetics of S-1 in 28 patients at doses of 25, 35, 40 and 45 mg/m(2). The plasma C(max) values of FT, 5-FU, oxonic acid and CDHP increased dose-dependently and after 1-2 h were in the ranges 5.8-13 microM, 0.4-2.4 microM, 0.026-1.337 microM, and 1.1-3.6 microM, respectively. Uracil levels, indicative of DPD inhibition, also increased dose-dependently from basal levels of 0.03-0.25 microM to 3.6-9.4 microM after 2-4 h, and 0.09-0.9 microM was still present after 24 h. The pharmacokinetics of CDHP and uracil were linear over the dose range. The areas under the plasma concentration curves (AUC) for CDHP and uracil were in the ranges 418-1735 and 2281-8627 micromol x min/l, respectively. The t(1/2) values were in the ranges 213-692 and 216-354 min, respectively. Cumulative urinary excretion of FT was predominantly as 5-FU and was 2.2-11.9%; the urinary excretion of both fluoro-beta-alanine and uracil was generally maximal between 6 and 18 h. During 28-day courses with twice-daily S-1 administration, 5-FU and uracil generally increased. Before each intake of S-1, 5-FU varied between 0.5 and 1 microM and uracil was in the micromolar range (up to 7 microM), indicating that effective DPD inhibition was maintained during the course. In a biopsy of an esophageal adenocarcinoma metastasis that had regressed, thymidylate synthase, the target of 5-FU, was inhibited 50%, but increased four- to tenfold after relapse in subsequent biopsies. In conclusion, oral S-1 administration resulted in prolonged exposure to micromolar 5-FU concentrations due to DPD inhibition, and the decrease in uracil levels after 6 h followed the pattern of CDHP and indicates reversible DPD inhibition.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-003-0617-9", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "52"
      }
    ], 
    "name": "Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors", 
    "pagination": "1-12", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "acd5d5a931367e586fac1b0057274724d5a4c95028c01520f1b3c8ad66ba43ff"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "12739060"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-003-0617-9"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1036282560"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-003-0617-9", 
      "https://app.dimensions.ai/details/publication/pub.1036282560"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T18:21", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8675_00000514.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00280-003-0617-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-003-0617-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-003-0617-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-003-0617-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-003-0617-9'


 

This table displays all metadata directly associated to this object as RDF triples.

382 TRIPLES      21 PREDICATES      94 URIs      41 LITERALS      29 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-003-0617-9 schema:about N0460a4e0b65d4fe6858e4cc8923fd666
2 N0774850a8d0440b193c912cac8cbf01e
3 N11947049a7f943daba43901b5aa19776
4 N1d108a1c3c5c4cfd9b742cf889a12b98
5 N2005171c6021415588c616a37f35afb7
6 N3796e99b901e416abb3207fa583b6567
7 N569a1c025f6c4978beac82b47ec68b77
8 N603b6d7bca6f48c99f43452222a8578b
9 N6a2a44c4c93442d2971539d6368586b1
10 N7c27673a1d624df5b193d1aedb657b5b
11 N80f6d09dbb6b4920b1d3150a4de09376
12 N8d954c15b7734687b384ac63e15d3bf2
13 N9889aaefef844ab2b7278a56b0e3b38a
14 N9f2d8bbcaf4b4dcaa84338e3211f02e2
15 Na75deea771bd42ba8593827c3dd7e3a6
16 Nb62e1de2a4a244b98ad6a9bb44bbd515
17 Nc48a82ff283b4e6a9ec7b7d1763bb458
18 Ncacdf1b09a104790a0ac1b4e57364de9
19 Neabd02110934451ea72cf394bca42a57
20 Neb1ef355df0c439f9bcf3ed5808333b4
21 anzsrc-for:11
22 anzsrc-for:1115
23 schema:author N827ef948bad646d0b9b008c5a5e1d8b6
24 schema:citation sg:pub.10.1007/978-1-59259-725-3_5
25 sg:pub.10.1007/bf00662639
26 sg:pub.10.1007/bf00685670
27 sg:pub.10.1007/s002800050561
28 sg:pub.10.1038/clpt.1980.156
29 https://app.dimensions.ai/details/publication/pub.1074255186
30 https://app.dimensions.ai/details/publication/pub.1074515759
31 https://app.dimensions.ai/details/publication/pub.1074570373
32 https://app.dimensions.ai/details/publication/pub.1074733629
33 https://app.dimensions.ai/details/publication/pub.1074797879
34 https://app.dimensions.ai/details/publication/pub.1076942345
35 https://app.dimensions.ai/details/publication/pub.1079562315
36 https://app.dimensions.ai/details/publication/pub.1079597830
37 https://app.dimensions.ai/details/publication/pub.1079977592
38 https://app.dimensions.ai/details/publication/pub.1080114929
39 https://app.dimensions.ai/details/publication/pub.1081600900
40 https://app.dimensions.ai/details/publication/pub.1082466563
41 https://app.dimensions.ai/details/publication/pub.1082895728
42 https://app.dimensions.ai/details/publication/pub.1083251777
43 https://app.dimensions.ai/details/publication/pub.1083320099
44 https://app.dimensions.ai/details/publication/pub.1083370636
45 https://doi.org/10.1001/archneur.1970.00480260061008
46 https://doi.org/10.1002/1097-0142(19911101)68:9<1903::aid-cncr2820680910>3.0.co;2-9
47 https://doi.org/10.1016/0006-2952(89)90187-1
48 https://doi.org/10.1016/0006-2952(94)00444-q
49 https://doi.org/10.1016/0277-5379(87)90053-8
50 https://doi.org/10.1016/0959-8049(93)90129-4
51 https://doi.org/10.1016/0959-8049(95)00217-7
52 https://doi.org/10.1016/s0378-4347(01)00203-1
53 https://doi.org/10.1016/s0378-4347(96)00429-x
54 https://doi.org/10.1016/s0925-4439(02)00082-0
55 https://doi.org/10.1016/s0959-8049(01)00371-9
56 https://doi.org/10.1016/s0959-8049(98)00058-6
57 https://doi.org/10.1054/drup.1999.0089
58 https://doi.org/10.1081/cnv-120000360
59 https://doi.org/10.1159/000138581
60 https://doi.org/10.1200/jco.1994.12.10.2035
61 https://doi.org/10.1200/jco.1998.16.1.301
62 https://doi.org/10.1200/jco.1998.16.4.1450
63 https://doi.org/10.1200/jco.1999.17.8.2439
64 https://doi.org/10.1200/jco.2000.18.14.2772
65 https://doi.org/10.1200/jco.2001.19.22.4267
66 https://doi.org/10.1517/13543784.5.6.637
67 https://doi.org/10.3109/00498259609046718
68 https://doi.org/10.3727/096504001108747729
69 schema:datePublished 2003-07
70 schema:datePublishedReg 2003-07-01
71 schema:description S-1 is an oral formulation of ftorafur (FT), oxonic acid and 5-chloro-2,4-dihydroxypyridine (CDHP) at a molar ratio of 1:0.4:1. FT is a 5-fluorouracil (5-FU) prodrug, CDHP is a dihydropyrimidine dehydrogenase (DPD) inhibitor and oxonic acid is an inhibitor of 5-FU phosphoribosylation in the gastrointestinal mucosa and was included to prevent gastrointestinal toxicity. We determined the pharmacokinetics of S-1 in 28 patients at doses of 25, 35, 40 and 45 mg/m(2). The plasma C(max) values of FT, 5-FU, oxonic acid and CDHP increased dose-dependently and after 1-2 h were in the ranges 5.8-13 microM, 0.4-2.4 microM, 0.026-1.337 microM, and 1.1-3.6 microM, respectively. Uracil levels, indicative of DPD inhibition, also increased dose-dependently from basal levels of 0.03-0.25 microM to 3.6-9.4 microM after 2-4 h, and 0.09-0.9 microM was still present after 24 h. The pharmacokinetics of CDHP and uracil were linear over the dose range. The areas under the plasma concentration curves (AUC) for CDHP and uracil were in the ranges 418-1735 and 2281-8627 micromol x min/l, respectively. The t(1/2) values were in the ranges 213-692 and 216-354 min, respectively. Cumulative urinary excretion of FT was predominantly as 5-FU and was 2.2-11.9%; the urinary excretion of both fluoro-beta-alanine and uracil was generally maximal between 6 and 18 h. During 28-day courses with twice-daily S-1 administration, 5-FU and uracil generally increased. Before each intake of S-1, 5-FU varied between 0.5 and 1 microM and uracil was in the micromolar range (up to 7 microM), indicating that effective DPD inhibition was maintained during the course. In a biopsy of an esophageal adenocarcinoma metastasis that had regressed, thymidylate synthase, the target of 5-FU, was inhibited 50%, but increased four- to tenfold after relapse in subsequent biopsies. In conclusion, oral S-1 administration resulted in prolonged exposure to micromolar 5-FU concentrations due to DPD inhibition, and the decrease in uracil levels after 6 h followed the pattern of CDHP and indicates reversible DPD inhibition.
72 schema:genre research_article
73 schema:inLanguage en
74 schema:isAccessibleForFree false
75 schema:isPartOf N850a1c4d1a0b45bb9bc2f44624ccf4fa
76 Ne4d192903c8f43a09f093b9fcb97d65e
77 sg:journal.1088364
78 schema:name Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors
79 schema:pagination 1-12
80 schema:productId N29caa909a50c4bf899711cbcb7ff5b4f
81 N31b18b6caef2446a834b248bd8486e73
82 N51b96f2fd76d43fa90c00ae953bd6654
83 Nb319d697402a466f81fbac38ceb96f01
84 Nbf867903c27a4e4486921e044f17150d
85 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036282560
86 https://doi.org/10.1007/s00280-003-0617-9
87 schema:sdDatePublished 2019-04-10T18:21
88 schema:sdLicense https://scigraph.springernature.com/explorer/license/
89 schema:sdPublisher Nc1fa8e0e1bd94edc8f75cd0268478965
90 schema:url http://link.springer.com/10.1007%2Fs00280-003-0617-9
91 sgo:license sg:explorer/license/
92 sgo:sdDataset articles
93 rdf:type schema:ScholarlyArticle
94 N0460a4e0b65d4fe6858e4cc8923fd666 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Fluorouracil
96 rdf:type schema:DefinedTerm
97 N0774850a8d0440b193c912cac8cbf01e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Drug Combinations
99 rdf:type schema:DefinedTerm
100 N0eb7065b65a34e10b35315e987466b26 rdf:first sg:person.01256606405.17
101 rdf:rest N532f45fc84fb42d4a1e8067c22113360
102 N0f4b4429e854439cae054a07070b3e6d rdf:first sg:person.01307713100.00
103 rdf:rest Na163513e26534806b1a673f5e3866c7a
104 N11947049a7f943daba43901b5aa19776 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Biological Availability
106 rdf:type schema:DefinedTerm
107 N1d108a1c3c5c4cfd9b742cf889a12b98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Female
109 rdf:type schema:DefinedTerm
110 N1f925fc408c84ae58809078db5e7dbe6 rdf:first sg:person.0600513472.36
111 rdf:rest Nba451bbcc1d64b13a0eef0d9d1d43dba
112 N2005171c6021415588c616a37f35afb7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Area Under Curve
114 rdf:type schema:DefinedTerm
115 N26284e9dddf14d15b03ab53eff5f3b2e rdf:first sg:person.01171546142.92
116 rdf:rest N86190c050d264f31ba3afa2635e71d40
117 N29caa909a50c4bf899711cbcb7ff5b4f schema:name nlm_unique_id
118 schema:value 7806519
119 rdf:type schema:PropertyValue
120 N31b18b6caef2446a834b248bd8486e73 schema:name dimensions_id
121 schema:value pub.1036282560
122 rdf:type schema:PropertyValue
123 N34a72ff420324065b0380dcafe77838b rdf:first sg:person.01304747074.35
124 rdf:rest N739f7dd20d71469582a35411339c80f3
125 N3796e99b901e416abb3207fa583b6567 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Metabolic Clearance Rate
127 rdf:type schema:DefinedTerm
128 N51b96f2fd76d43fa90c00ae953bd6654 schema:name pubmed_id
129 schema:value 12739060
130 rdf:type schema:PropertyValue
131 N532f45fc84fb42d4a1e8067c22113360 rdf:first sg:person.01346612643.05
132 rdf:rest N93121611d434450aa7e4fda4de37071b
133 N569a1c025f6c4978beac82b47ec68b77 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Neoplasms
135 rdf:type schema:DefinedTerm
136 N5eb1327f76c5491386a70abca85718a5 schema:name EORTC—New Drug Development Group, Nantes, France
137 rdf:type schema:Organization
138 N603b6d7bca6f48c99f43452222a8578b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Tegafur
140 rdf:type schema:DefinedTerm
141 N6a2a44c4c93442d2971539d6368586b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Uracil
143 rdf:type schema:DefinedTerm
144 N739f7dd20d71469582a35411339c80f3 rdf:first sg:person.01101667531.56
145 rdf:rest Ncadcbfe3301c468a95c60e8fc4e6238a
146 N7b3c6f6cc80e4de9a5d638bb6735ec7c rdf:first sg:person.01232364243.35
147 rdf:rest N34a72ff420324065b0380dcafe77838b
148 N7c27673a1d624df5b193d1aedb657b5b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Antimetabolites, Antineoplastic
150 rdf:type schema:DefinedTerm
151 N80f6d09dbb6b4920b1d3150a4de09376 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Aged
153 rdf:type schema:DefinedTerm
154 N827ef948bad646d0b9b008c5a5e1d8b6 rdf:first sg:person.01255301342.17
155 rdf:rest N26284e9dddf14d15b03ab53eff5f3b2e
156 N850a1c4d1a0b45bb9bc2f44624ccf4fa schema:volumeNumber 52
157 rdf:type schema:PublicationVolume
158 N86190c050d264f31ba3afa2635e71d40 rdf:first sg:person.010124200377.90
159 rdf:rest N1f925fc408c84ae58809078db5e7dbe6
160 N8d954c15b7734687b384ac63e15d3bf2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Oxonic Acid
162 rdf:type schema:DefinedTerm
163 N8f9f22b63a494b78bf55db985cd1656c schema:name NDDO Oncology, Amsterdam, The Netherlands
164 rdf:type schema:Organization
165 N93121611d434450aa7e4fda4de37071b rdf:first sg:person.01220376041.48
166 rdf:rest N0f4b4429e854439cae054a07070b3e6d
167 N9889aaefef844ab2b7278a56b0e3b38a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Tissue Distribution
169 rdf:type schema:DefinedTerm
170 N9f2d8bbcaf4b4dcaa84338e3211f02e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Male
172 rdf:type schema:DefinedTerm
173 Na163513e26534806b1a673f5e3866c7a rdf:first sg:person.01347171204.78
174 rdf:rest N7b3c6f6cc80e4de9a5d638bb6735ec7c
175 Na75deea771bd42ba8593827c3dd7e3a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Dose-Response Relationship, Drug
177 rdf:type schema:DefinedTerm
178 Nb00cde1fe89f4698ab6ca839e58c1c96 rdf:first sg:person.0606744057.67
179 rdf:rest N0eb7065b65a34e10b35315e987466b26
180 Nb319d697402a466f81fbac38ceb96f01 schema:name readcube_id
181 schema:value acd5d5a931367e586fac1b0057274724d5a4c95028c01520f1b3c8ad66ba43ff
182 rdf:type schema:PropertyValue
183 Nb62e1de2a4a244b98ad6a9bb44bbd515 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Middle Aged
185 rdf:type schema:DefinedTerm
186 Nba451bbcc1d64b13a0eef0d9d1d43dba rdf:first sg:person.01023051473.48
187 rdf:rest Nb00cde1fe89f4698ab6ca839e58c1c96
188 Nbf867903c27a4e4486921e044f17150d schema:name doi
189 schema:value 10.1007/s00280-003-0617-9
190 rdf:type schema:PropertyValue
191 Nc1fa8e0e1bd94edc8f75cd0268478965 schema:name Springer Nature - SN SciGraph project
192 rdf:type schema:Organization
193 Nc48a82ff283b4e6a9ec7b7d1763bb458 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Humans
195 rdf:type schema:DefinedTerm
196 Ncacdf1b09a104790a0ac1b4e57364de9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Half-Life
198 rdf:type schema:DefinedTerm
199 Ncadcbfe3301c468a95c60e8fc4e6238a rdf:first sg:person.016122500204.87
200 rdf:rest rdf:nil
201 Ne4d192903c8f43a09f093b9fcb97d65e schema:issueNumber 1
202 rdf:type schema:PublicationIssue
203 Neabd02110934451ea72cf394bca42a57 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Pyridines
205 rdf:type schema:DefinedTerm
206 Neb1ef355df0c439f9bcf3ed5808333b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Adult
208 rdf:type schema:DefinedTerm
209 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
210 schema:name Medical and Health Sciences
211 rdf:type schema:DefinedTerm
212 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
213 schema:name Pharmacology and Pharmaceutical Sciences
214 rdf:type schema:DefinedTerm
215 sg:journal.1088364 schema:issn 0344-5704
216 1432-0843
217 schema:name Cancer Chemotherapy and Pharmacology
218 rdf:type schema:Periodical
219 sg:person.010124200377.90 schema:affiliation https://www.grid.ac/institutes/grid.5650.6
220 schema:familyName Van Kuilenburg
221 schema:givenName A. B. P.
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010124200377.90
223 rdf:type schema:Person
224 sg:person.01023051473.48 schema:affiliation https://www.grid.ac/institutes/grid.16872.3a
225 schema:familyName Gall
226 schema:givenName H.
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023051473.48
228 rdf:type schema:Person
229 sg:person.01101667531.56 schema:affiliation N5eb1327f76c5491386a70abca85718a5
230 schema:familyName Fumoleau
231 schema:givenName P.
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01101667531.56
233 rdf:type schema:Person
234 sg:person.01171546142.92 schema:affiliation https://www.grid.ac/institutes/grid.16872.3a
235 schema:familyName Noordhuis
236 schema:givenName P.
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171546142.92
238 rdf:type schema:Person
239 sg:person.01220376041.48 schema:affiliation https://www.grid.ac/institutes/grid.5650.6
240 schema:familyName Van Gennip
241 schema:givenName A. H.
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220376041.48
243 rdf:type schema:Person
244 sg:person.01232364243.35 schema:affiliation https://www.grid.ac/institutes/grid.16872.3a
245 schema:familyName Smid
246 schema:givenName K.
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232364243.35
248 rdf:type schema:Person
249 sg:person.01255301342.17 schema:affiliation https://www.grid.ac/institutes/grid.16872.3a
250 schema:familyName Peters
251 schema:givenName G. J.
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255301342.17
253 rdf:type schema:Person
254 sg:person.01256606405.17 schema:affiliation https://www.grid.ac/institutes/grid.430814.a
255 schema:familyName Swart
256 schema:givenName M. S.
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01256606405.17
258 rdf:type schema:Person
259 sg:person.01304747074.35 schema:affiliation https://www.grid.ac/institutes/grid.16872.3a
260 schema:familyName Giaccone
261 schema:givenName G.
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304747074.35
263 rdf:type schema:Person
264 sg:person.01307713100.00 schema:affiliation N8f9f22b63a494b78bf55db985cd1656c
265 schema:familyName Wanders
266 schema:givenName J.
267 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307713100.00
268 rdf:type schema:Person
269 sg:person.01346612643.05 schema:affiliation https://www.grid.ac/institutes/grid.16872.3a
270 schema:familyName Voorn
271 schema:givenName D.
272 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346612643.05
273 rdf:type schema:Person
274 sg:person.01347171204.78 schema:affiliation https://www.grid.ac/institutes/grid.16872.3a
275 schema:familyName Holwerda
276 schema:givenName U.
277 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347171204.78
278 rdf:type schema:Person
279 sg:person.016122500204.87 schema:affiliation https://www.grid.ac/institutes/grid.16872.3a
280 schema:familyName Van Groeningen
281 schema:givenName C. J.
282 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016122500204.87
283 rdf:type schema:Person
284 sg:person.0600513472.36 schema:affiliation https://www.grid.ac/institutes/grid.430814.a
285 schema:familyName Schornagel
286 schema:givenName J. H.
287 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0600513472.36
288 rdf:type schema:Person
289 sg:person.0606744057.67 schema:affiliation https://www.grid.ac/institutes/grid.430814.a
290 schema:familyName Turner
291 schema:givenName S. L.
292 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0606744057.67
293 rdf:type schema:Person
294 sg:pub.10.1007/978-1-59259-725-3_5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035390634
295 https://doi.org/10.1007/978-1-59259-725-3_5
296 rdf:type schema:CreativeWork
297 sg:pub.10.1007/bf00662639 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026508229
298 https://doi.org/10.1007/bf00662639
299 rdf:type schema:CreativeWork
300 sg:pub.10.1007/bf00685670 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017013439
301 https://doi.org/10.1007/bf00685670
302 rdf:type schema:CreativeWork
303 sg:pub.10.1007/s002800050561 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028328879
304 https://doi.org/10.1007/s002800050561
305 rdf:type schema:CreativeWork
306 sg:pub.10.1038/clpt.1980.156 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041499966
307 https://doi.org/10.1038/clpt.1980.156
308 rdf:type schema:CreativeWork
309 https://app.dimensions.ai/details/publication/pub.1074255186 schema:CreativeWork
310 https://app.dimensions.ai/details/publication/pub.1074515759 schema:CreativeWork
311 https://app.dimensions.ai/details/publication/pub.1074570373 schema:CreativeWork
312 https://app.dimensions.ai/details/publication/pub.1074733629 schema:CreativeWork
313 https://app.dimensions.ai/details/publication/pub.1074797879 schema:CreativeWork
314 https://app.dimensions.ai/details/publication/pub.1076942345 schema:CreativeWork
315 https://app.dimensions.ai/details/publication/pub.1079562315 schema:CreativeWork
316 https://app.dimensions.ai/details/publication/pub.1079597830 schema:CreativeWork
317 https://app.dimensions.ai/details/publication/pub.1079977592 schema:CreativeWork
318 https://app.dimensions.ai/details/publication/pub.1080114929 schema:CreativeWork
319 https://app.dimensions.ai/details/publication/pub.1081600900 schema:CreativeWork
320 https://app.dimensions.ai/details/publication/pub.1082466563 schema:CreativeWork
321 https://app.dimensions.ai/details/publication/pub.1082895728 schema:CreativeWork
322 https://app.dimensions.ai/details/publication/pub.1083251777 schema:CreativeWork
323 https://app.dimensions.ai/details/publication/pub.1083320099 schema:CreativeWork
324 https://app.dimensions.ai/details/publication/pub.1083370636 schema:CreativeWork
325 https://doi.org/10.1001/archneur.1970.00480260061008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024508314
326 rdf:type schema:CreativeWork
327 https://doi.org/10.1002/1097-0142(19911101)68:9<1903::aid-cncr2820680910>3.0.co;2-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036845106
328 rdf:type schema:CreativeWork
329 https://doi.org/10.1016/0006-2952(89)90187-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027438015
330 rdf:type schema:CreativeWork
331 https://doi.org/10.1016/0006-2952(94)00444-q schema:sameAs https://app.dimensions.ai/details/publication/pub.1012048074
332 rdf:type schema:CreativeWork
333 https://doi.org/10.1016/0277-5379(87)90053-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036522081
334 rdf:type schema:CreativeWork
335 https://doi.org/10.1016/0959-8049(93)90129-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044367856
336 rdf:type schema:CreativeWork
337 https://doi.org/10.1016/0959-8049(95)00217-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041155362
338 rdf:type schema:CreativeWork
339 https://doi.org/10.1016/s0378-4347(01)00203-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016987868
340 rdf:type schema:CreativeWork
341 https://doi.org/10.1016/s0378-4347(96)00429-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1046560228
342 rdf:type schema:CreativeWork
343 https://doi.org/10.1016/s0925-4439(02)00082-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026544769
344 rdf:type schema:CreativeWork
345 https://doi.org/10.1016/s0959-8049(01)00371-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008444022
346 rdf:type schema:CreativeWork
347 https://doi.org/10.1016/s0959-8049(98)00058-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004034553
348 rdf:type schema:CreativeWork
349 https://doi.org/10.1054/drup.1999.0089 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000143703
350 rdf:type schema:CreativeWork
351 https://doi.org/10.1081/cnv-120000360 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018308252
352 rdf:type schema:CreativeWork
353 https://doi.org/10.1159/000138581 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027697939
354 rdf:type schema:CreativeWork
355 https://doi.org/10.1200/jco.1994.12.10.2035 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082570398
356 rdf:type schema:CreativeWork
357 https://doi.org/10.1200/jco.1998.16.1.301 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083201650
358 rdf:type schema:CreativeWork
359 https://doi.org/10.1200/jco.1998.16.4.1450 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083246640
360 rdf:type schema:CreativeWork
361 https://doi.org/10.1200/jco.1999.17.8.2439 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074549863
362 rdf:type schema:CreativeWork
363 https://doi.org/10.1200/jco.2000.18.14.2772 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074667570
364 rdf:type schema:CreativeWork
365 https://doi.org/10.1200/jco.2001.19.22.4267 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074954342
366 rdf:type schema:CreativeWork
367 https://doi.org/10.1517/13543784.5.6.637 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025883442
368 rdf:type schema:CreativeWork
369 https://doi.org/10.3109/00498259609046718 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029977116
370 rdf:type schema:CreativeWork
371 https://doi.org/10.3727/096504001108747729 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074838513
372 rdf:type schema:CreativeWork
373 https://www.grid.ac/institutes/grid.16872.3a schema:alternateName VU University Medical Center
374 schema:name Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands
375 Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands
376 rdf:type schema:Organization
377 https://www.grid.ac/institutes/grid.430814.a schema:alternateName Antoni van Leeuwenhoek Hospital
378 schema:name Department of Internal Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands
379 rdf:type schema:Organization
380 https://www.grid.ac/institutes/grid.5650.6 schema:alternateName Academic Medical Center
381 schema:name Laboratory of Genetic Metabolic Diseases, Academic Medical Center, Amsterdam, The Netherlands
382 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...